Lineage Cell Therapeutics, Inc. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Lineage Cell Therapeutics, Inc. (LCTX) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $162.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-03-05
- Lineage Cell Therapeutics, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $162.00K, a 14.74% decline from fiscal 2024.
- Lineage Cell Therapeutics, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $190.00K, a 46.33% decline from fiscal 2023.
- Lineage Cell Therapeutics, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $354.00K.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month |
|---|---|
| 2025-12-31 | $162.00K 10-K · filed 2026-03-05 |
| 2024-12-31 | $190.00K 10-K · filed 2026-03-05 |
| 2023-12-31 | $354.00K 10-K · filed 2025-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |